EREG overexpression
|
CRC
|
EREG overexpression
|
CRC
|
panitumumab Sensitive: B - Late Trials
|
panitumumab Sensitive: B - Late Trials
|
EREG overexpression
|
CRC
|
EREG overexpression
|
CRC
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EGFR inhibitor Sensitive: C3 – Early Trials
|
EREG overexpression
|
Pancreatic Cancer
|
EREG overexpression
|
Pancreatic Cancer
|
cetuximab Resistant: C4 – Case Studies
|
cetuximab Resistant: C4 – Case Studies
|